Literature DB >> 18407567

Multiple diseases in carrier probability estimation: accounting for surviving all cancers other than breast and ovary in BRCAPRO.

Hormuzd A Katki1, Amanda Blackford, Sining Chen, Giovanni Parmigiani.   

Abstract

Mendelian models can predict who carries an inherited deleterious mutation of known disease genes based on family history. For example, the BRCAPRO model is commonly used to identify families who carry mutations of BRCA1 and BRCA2, based on familial breast and ovarian cancers. These models incorporate the age of diagnosis of diseases in relatives and current age or age of death. We develop a rigorous foundation for handling multiple diseases with censoring. We prove that any disease unrelated to mutations can be excluded from the model, unless it is sufficiently common and dependent on a mutation-related disease time. Furthermore, if a family member has a disease with higher probability density among mutation carriers, but the model does not account for it, then the carrier probability is deflated. However, even if a family only has diseases the model accounts for, if the model excludes a mutation-related disease, then the carrier probability will be inflated. In light of these results, we extend BRCAPRO to account for surviving all non-breast/ovary cancers as a single outcome. The extension also enables BRCAPRO to extract more useful information from male relatives. Using 1500 families from the Cancer Genetics Network, accounting for surviving other cancers improves BRCAPRO's concordance index from 0.758 to 0.762 (p=0.046), improves its positive predictive value from 35 to 39 per cent (p<10(-6)) without impacting its negative predictive value, and improves its overall calibration, although calibration slightly worsens for those with carrier probability<10 per cent. Copyright (c) 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2008        PMID: 18407567      PMCID: PMC2562929          DOI: 10.1002/sim.3302

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  25 in total

1.  BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian.

Authors:  Bernard Friedenson
Journal:  MedGenMed       Date:  2005-06-29

2.  Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.

Authors:  D A Berry; G Parmigiani; J Sanchez; J Schildkraut; E Winer
Journal:  J Natl Cancer Inst       Date:  1997-02-05       Impact factor: 13.506

3.  Evaluating the yield of medical tests.

Authors:  F E Harrell; R M Califf; D B Pryor; K L Lee; R A Rosati
Journal:  JAMA       Date:  1982-05-14       Impact factor: 56.272

4.  Cancer risks in BRCA2 mutation carriers.

Authors: 
Journal:  J Natl Cancer Inst       Date:  1999-08-04       Impact factor: 13.506

Review 5.  Application of breast cancer risk prediction models in clinical practice.

Authors:  Susan M Domchek; Andrea Eisen; Kathleen Calzone; Jill Stopfer; Anne Blackwood; Barbara L Weber
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

6.  Prediction of germline mutations and cancer risk in the Lynch syndrome.

Authors:  Sining Chen; Wenyi Wang; Shing Lee; Khedoudja Nafa; Johanna Lee; Kathy Romans; Patrice Watson; Stephen B Gruber; David Euhus; Kenneth W Kinzler; Jeremy Jass; Steven Gallinger; Noralane M Lindor; Graham Casey; Nathan Ellis; Francis M Giardiello; Kenneth Offit; Giovanni Parmigiani
Journal:  JAMA       Date:  2006-09-27       Impact factor: 56.272

7.  Optimal selection of individuals for BRCA mutation testing: a comparison of available methods.

Authors:  Paul A James; Rebecca Doherty; Marion Harris; Bickol N Mukesh; Alvin Milner; Mary-Anne Young; Clare Scott
Journal:  J Clin Oncol       Date:  2006-02-01       Impact factor: 44.544

8.  Cancer Incidence in BRCA1 mutation carriers.

Authors:  Deborah Thompson; Douglas F Easton
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

9.  Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  Kelly Metcalfe; Henry T Lynch; Parviz Ghadirian; Nadine Tung; Ivo Olivotto; Ellen Warner; Olufunmilayo I Olopade; Andrea Eisen; Barbara Weber; Jane McLennan; Ping Sun; William D Foulkes; Steven A Narod
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

10.  Incorporating medical interventions into carrier probability estimation for genetic counseling.

Authors:  Hormuzd A Katki
Journal:  BMC Med Genet       Date:  2007-03-22       Impact factor: 2.103

View more
  12 in total

1.  Reclassification of predictions for uncovering subgroup specific improvement.

Authors:  Swati Biswas; Banu Arun; Giovanni Parmigiani
Journal:  Stat Med       Date:  2013-12-18       Impact factor: 2.373

2.  Simpson's paradox in the integrated discrimination improvement.

Authors:  J Chipman; D Braun
Journal:  Stat Med       Date:  2016-01-05       Impact factor: 2.373

3.  Estimating TP53 Mutation Carrier Probability in Families with Li-Fraumeni Syndrome Using LFSPRO.

Authors:  Gang Peng; Jasmina Bojadzieva; Mandy L Ballinger; Jialu Li; Amanda L Blackford; Phuong L Mai; Sharon A Savage; David M Thomas; Louise C Strong; Wenyi Wang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-01-30       Impact factor: 4.254

4.  A two-stage approach to genetic risk assessment in primary care.

Authors:  Swati Biswas; Philamer Atienza; Jonathan Chipman; Amanda L Blackford; Banu Arun; Kevin Hughes; Giovanni Parmigiani
Journal:  Breast Cancer Res Treat       Date:  2016-01-19       Impact factor: 4.872

5.  A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of BRCA1/2.

Authors:  Ana F Best; Margaret A Tucker; Megan N Frone; Mark H Greene; June A Peters; Hormuzd A Katki
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-01-28       Impact factor: 4.254

6.  Providing access to risk prediction tools via the HL7 XML-formatted risk web service.

Authors:  Jonathan Chipman; Brian Drohan; Amanda Blackford; Giovanni Parmigiani; Kevin Hughes; Phil Bosinoff
Journal:  Breast Cancer Res Treat       Date:  2013-06-23       Impact factor: 4.872

7.  Frailty-based competing risks model for multivariate survival data.

Authors:  Malka Gorfine; Li Hsu
Journal:  Biometrics       Date:  2010-08-05       Impact factor: 2.571

8.  Calibrated predictions for multivariate competing risks models.

Authors:  Malka Gorfine; Li Hsu; David M Zucker; Giovanni Parmigiani
Journal:  Lifetime Data Anal       Date:  2013-05-31       Impact factor: 1.588

9.  Simplifying clinical use of the genetic risk prediction model BRCAPRO.

Authors:  Swati Biswas; Philamer Atienza; Jonathan Chipman; Kevin Hughes; Angelica M Gutierrez Barrera; Christopher I Amos; Banu Arun; Giovanni Parmigiani
Journal:  Breast Cancer Res Treat       Date:  2013-05-21       Impact factor: 4.872

10.  Modeling of successive cancer risks in Lynch syndrome families in the presence of competing risks using copulas.

Authors:  Yun-Hee Choi; Laurent Briollais; Aung K Win; John Hopper; Dan Buchanan; Mark Jenkins; Lajmi Lakhal-Chaieb
Journal:  Biometrics       Date:  2016-07-05       Impact factor: 1.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.